Article
Clinical and Hemodynamic Characterization Super Responders to IV Prostacyclin in Pulmonary Arterial Hypertension
2021-02-08
Abstract excerpt
<h4>Background: </h4> Parenteral prostacyclins are the only therapy proven to extend survival in pulmonary arterial hypertension (PAH), yet at the bedside clinicians have no tools to predict which patients are most likely to benefit from this medication class. <h4>Methods: </h4>: We retrospectively analyzed all PAH patients treated with IV epoprostenol therapy at our center from 1/1/1996 to 12/31/2016. We analyzed...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b399aeb5-31d4-53a5-bce2-09e73451ac36
- DOI
- 10.21203/rs.3.rs-70022/v2
